Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TITANium: AZD5492 in relapsed or refractory CD20-positive B-cell malignancies
jRCT2031240426Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2024
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label trial of AZD5492 in B-cell malignancy, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 2 more (2 arms), sponsored by AstraZeneca. Primary endpoints: Frequency of dose-limiting toxicities, Safety and 1 more. Started Nov 2024; status: recruiting.
02
Drugs
AZD5492
03
Conditions
B-cell malignancydiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on jRCT2031240426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240426.